Oncology · ChemotherapyRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental Application for Methotrexate Sodium by Strides Pharma

Importance6/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Strides Pharma12 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 6:32:23 PM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Strides Pharma's supplemental application for Methotrexate Sodium is a significant regulatory milestone that could strengthen their competitive position in the oncology market. Portfolio teams should evaluate the implications for market dynamics and competitor strategies. Regulatory context from FDA (FDA AP — METHOTREXATE SODIUM (ORIG)) supports the near-term read. Assessment grounded in 27 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and positioning of Methotrexate Sodium against competitors. The strongest clinical anchor is A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (astrazeneca). In Oncology · Chemotherapy, 8 regulatory and 4 competitive items passed relevance filtering for Strides Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Supplemental Application for Retevmo (Selpercatinib) (Humanexa Signals) — sponsor/company relevance (lilly). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This acceptance may enhance Strides Pharma's position in the oncology market, particularly in chemotherapy treatments.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHOTREXATE SODIUM (ORIG) (FDA). Entity match (methotrexate sodium). The acceptance indicates a positive regulatory trajectory, but further monitoring is necessary to assess the approval timeline and any additional requirements.

Key Risks

Elevated medium regulatory exposure for Strides Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, this could enhance Strides Pharma's market share in chemotherapy, potentially impacting revenue streams for competing products.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Portfolio teams should assess the potential market impact and positioning of Methotrexate Sodium against competitors.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the approval timeline and any additional data that may support the application.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium)
FDA document
View source
FDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ACETAZOLAMIDE SODIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Supplemental Application for Retevmo (Selpercatinib)
Humanexa Signalshigh relevance
Sponsor/company relevance (Lilly)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental NDA for Linzess by AbbVie
Humanexa Signalsmedium relevance
Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intramuscular patient-derived xenografts achieve high engraftment rates in gastric cancer: implications for pharmacodynamic testing and genomic biomarker discovery.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Strides Pharma
Methotrexate Sodium

Commercial impact

medium

If approved, this could enhance Strides Pharma's market share in chemotherapy, potentially impacting revenue streams for competing products.

Regulatory impact

medium

The acceptance indicates a positive regulatory trajectory, but further monitoring is necessary to assess the approval timeline and any additional requirements.

What to watch

Monitor for further updates on the approval timeline and any additional data that may support the application.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.